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SUMMARY
Invasion of surrounding brain tissue by isolated tumor cells represents one of the main obstacles to a curative
therapy of glioblastoma multiforme. Here we unravel a mechanism regulating glioma infiltration. Tumor inter-
action with the surrounding brain tissue induces CD95 Ligand expression. Binding of CD95 Ligand to CD95
on glioblastoma cells recruits the Src family member Yes and the p85 subunit of phosphatidylinositol
3-kinase to CD95, which signal invasion via the glycogen synthase kinase 3-b pathway and subsequent
expression of matrix metalloproteinases. In a murine syngeneic model of intracranial GBM, neutralization
of CD95 activity dramatically reduced the number of invading cells. Our results uncover CD95 as an activator
of PI3K and, most importantly, as a crucial trigger of basal invasion of glioblastoma in vivo.INTRODUCTION
The most frequent glioma (65%) is the glioblastoma multiforme
(GBM), with a median survival of 10–12 months (Kleihues et al.,
1993). Main obstacles to an effective therapy are invasion of
migrating tumor cells into the normal surrounding brain tissue
(host) and cellular resistance to multiple apoptotic stimuli. The
CD95/CD95 Ligand (CD95L; Apo1L/FasL) death system is best
described as an apoptosis inducer. Binding of trimerized CD95L
to the CD95 receptor leads to recruitment of the adaptor protein
FADD (Fas-associated death domain, MORT1) (Kischkel et al.,1995) and Caspase-8 and -10 into a death-inducing signaling
complex (DISC) (Kischkel et al., 2001). FADD contains a death do-
main (DD) and a death-effector domain (DED). Via its DD, FADD
binds to the DD of CD95 (Boldin et al., 1995). The DED recruits
the DED-containing pro-Caspase-8 into the DISC, where it is ac-
tivated through self-cleavage and commits the cell to apoptosis
by activation of downstream effector caspases (Medema et al.,
1997; Scaffidi et al., 1998). In this study we show that this signaling
cascade is, however, absent in apoptosis-resistant GBM.
Src family kinases (SFKs) are nonreceptor tyrosine kinases
participating in induction of GBM invasion (Park et al., 2006).SIGNIFICANCE
Glioblastoma multiforme typically have diffuse, infiltrative growth patterns that hinder the achievement of complete surgical
resection. Current treatment modalities aim at inducing apoptosis of remaining tumor cells in part by inducing expression of
the death system CD95/CD95L. Overcoming resistance of tumor cells to CD95-induced apoptosis has been in the limelight
of cancer research. We, however, found that tumor cells take advantage of CD95 to increase their infiltration capacity.
Further, tumor cells even induce expression of the ligand for CD95 in the surrounding tissue. Thus, contrary to expectations,
inhibition and not induction of the death system CD95/CD95L should be considered as frontline therapy for GBM.Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc. 235
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CD95 Triggers Invasion of Glioblastoma CellsSFKs activate phosphatidylinositol 3-kinase (PI3K) by direct
phosphorylation of the regulatory subunit p85, as well as by
phosphorylation of other proteins that can ultimately activate
PI3K (Thomas and Brugge, 1997). Activation of SFKs involves
interaction with partner proteins, as well as dephosphorylation
of tyrosine residue 527 in the C-terminal domain (Tyr527). This
provokes a conformational change allowing phosphorylation of
tyrosine 416 in the activation loop (Tyr416), which is important
for full activation of SFKs (Boggon and Eck, 2004).
We could show that in GBM samples from patients CD95L was
highly expressed at the site of tumor/host interaction—the inva-
sion front—by tumor cells and cells within the surrounding brain
parenchyma, mostly neurons. A large population of GBM cells is,
however, resistant to CD95-induced apoptosis. While current
efforts are aimed at sensitizing these cells to CD95-mediated
apoptosis, the possibility that CD95 might signal tumorigenesis
has been largely ignored. Here, we detected an association of
the Src family member Yes and the p85 subunit of PI3K to
CD95. Activated PI3K leads to inhibition of glycogen synthase
kinase 3-b (GSK3b) and induction of matrix metalloproteinases
(MMPs). In intracranial GBM, neutralization of CD95 activity dra-
matically reduced the number of cells invading the contralateral
hemisphere. Our study identifies CD95 as a major contributor to
the invasion-prone phenotype of GBM and thus defines it as
a prime target for future therapy.
RESULTS
CD95 Mediates Invasion of Glioblastoma
Cells Resistant to Apoptosis
In established human malignant glioma cell lines, we first exam-
ined the induction of apoptosis upon triggering of CD95. The
potency to activate CD95 proportionally correlates with the de-
gree of oligomerization of CD95L. Since the available CD95L
has a tendency to form aggregates, we engineered a human
CD95L with a stable trimer-building capacity, the CD95L-T4 (Fig-
ure S1 available online). Different glioma cell lines exhibited dif-
ferent sensitivities to treatment with CD95L-T4: apoptosis was
induced already at low concentrations in LN18 cells but not in
T98G cells (Figure 1A). Specificity of CD95L-T4-induced death
was tested by the neutralization of apoptosis by an antibody to
CD95L (NOK1; Figure S3). Both LN18 and T98G cell lines, how-
ever, exhibited comparably high levels of CD95 surface expres-
sion (Figure 1A). These cell lines also expressed other molecules
necessary for CD95-mediated apoptosis, such as FADD, Cas-
pase-8, or Caspase-3 (Figures 5C and 5D) (Karmakar et al.,
2006; Kugler et al., 2002).
Malignant glioma cells are characterized by their resistance to
apoptosis, replicative potential, induction of angiogenesis, and
migration/invasion. Stimulation of CD95 did not alter the prolifer-
ation rate of T98G cells (data not shown). We further examined
CD95-induced migration through collagen-coated transwell
inserts. Treatment with CD95L increased migration of T98G
but not of LN18 cells (Figure 1B).
The migration of glioma cells requires cleavage of extracellular
matrix components through MMPs. In T98G cells, MMP-9 activ-
ity, as assessed by gel zymography, increased upon treatment
with CD95L-T4 (Figure 1C). Accordingly, stimulation of CD95
increased expression of MMP-2 and MMP-9 mRNA levels in236 Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc.the migration-prone T98G but not in the apoptosis-sensitive
LN18 cells (Figures 1D and 1E). Most importantly, CD95-induced
migration of T98G cells could be blocked with siRNA pool
against MMP-2 and -9, indicating that these MMPs are required
for CD95-induced migration (Figures 1F and 1G).
In a further series of experiments we used short-term glioma
cultures derived from patients’ tumors. These cells exhibited
the typical GBM-genetic aberrations, including single-copy los-
ses of the PTEN and CDKN2a loci and single-copy gain of the
c-erbB (EGFR) locus, as assessed by array-CGH analyses
(B. Radlwimmer, personal communication). Every primary GBM-
derived culture examined here exhibited high CD95 surface
expression (n = 18) and similar or higher levels of resistance to
CD95-induced apoptosis (n = 8) compared to the ones observed
in the invasion-prone T98G cell line (Figure 2A, Figure S2, and
data not shown). Both the levels of CD95 surface expression
and the resistance to CD95-mediated apoptosis were not
affected by the number of passages in culture (data not shown).
We further examined CD95-induced invasion in the GBM-de-
rived cultures NCH89, NCH125, and NCH270. Triggering of
CD95 in NCH125 and NCH270 increased expression of MMP-
2 and MMP-9 and subsequently induced migration (Figures
2B–2D). Stimulation of CD95 in NCH89 cells increased neither
migration nor expression of MMP-9 (Figures 2B–2D). Thus, the
migration response to CD95 does not strictly correlate with the
degree of resistance to apoptosis. Along the same line, expres-
sion of CD95 and CD95L mRNA differed among the highly inva-
sive primary GBM tumors tested (Figure S2). MMPs are required
for CD95L-T4-induced migration of NCH125, as a siRNA pool to
MMP-2 and -9 significantly blocked migration (Figure 2E).
CD95 Mediates Invasion via the PI3K/GSK3b/MMP
Pathway
One of the best described inducers of GBM invasion is EGF. Its
binding to EGFR promotes MMP-9 expression through activa-
tion of the MAPK/ERK and the PI3K pathway (Rao, 2003). PI3K
activates AKT/PKB, which in turn is able to phosphorylate
GSK3b, leading to its inactivation. To test if PI3K or MAPK signal-
ing could be responsible for the observed invasion, we deter-
mined phosphorylation of ERK and AKT. Stimulation of T98G
and LN18 cells with CD95L-T4 activated AKT but not ERK
(Figure 3A). Interestingly, ERK activity was even blocked with
increasing time following stimulation (Figure 3A). In the inva-
sion-prone T98G, NCH125, and NCH270 cells, phosphorylation
of AKT exhibited a concentration-dependent bell-shaped curve
(Figure 3B). In contrast, in NCH89 cells, which did not react to
CD95 with increased invasion, CD95L-T4 did not activate AKT
above basal levels (Figure 3B). Inhibition of GSK3b via phosphor-
ylation at its serine-9 (phospho-ser9) was observed in T98G cells
upon treatment with CD95L-T4 or aApo-1 antibody by western
blot and FACS staining (Figure 3C and Figure S3).
Overexpression of a constitutively active GSK3b mutant (GSK
S9A) via lentiviral infection blocked CD95-induced migration of
T98G cells (Figure 3D). GSK S9A-expressing T98G cells and their
wild-type counterparts exhibited comparable growth rate and
levels of sensitivity to CD95-induced apoptosis (Figure S3).
Thus, inhibition of migration by constitutively active GSK3b in
T98G cells cannot be attributed to a different proliferation rate.
Active GSK3b forms a complex with b-catenin, the adenomatous
Cancer Cell
CD95 Triggers Invasion of Glioblastoma CellsFigure 1. CD95 Triggers Invasion of Apoptosis-Resistant Cells via MMPs
(A) The glioblastoma cell lines T98G and LN18 were incubated with the indicated concentrations of CD95L-T4 or Staurosporin (St., 1 mM) or left untreated (Co).
After 24 hr DNA fragmentation was analyzed by FACS (upper panel). (Lower panel) FACS analysis of CD95 surface expression in the T98G and LN18.
(B) T98G and LN18 cells were treated with CD95L-T4 or left untreated, to detect single-cell migration through a Boyden chamber with 8 mm pore size.
(C) T98G cells were treated with CD95L-T4 for 24 hr or left untreated. Thereafter, MMP-9 activity was assessed by Gel Zymography.
(D and E) T98G and LN18 cells were treated with aApo-1 for 48 hr or left untreated. Expression of MMP-2 and MMP-9 was measured by quantitative real-time
PCR. Data are results from five independent experiments as mean ± SE, *p < 0.05.
(F) T98G cells were transfected with a siRNA pool against MMP-2 and MMP-9 (shMMPs) or with Lipofectamine alone (Lipo). Forty-eight hours after transfection,
cells were treated with CD95L-T4; 48 hr afterwards migration was measured in a two-dimensional migration assay.
(G) Expression of MMP-2 and MMP-9 as measured by quantitative-RT-PCR.
(A, B, and D–F) Results are expressed as mean ± SE (*p < 0.05; **p < 0.001; ***p < 0.0001) and are representative of at least two independent experiments.Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc. 237
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CD95 Triggers Invasion of Glioblastoma CellsFigure 2. CD95 Triggers Invasion of Primary Apoptosis-Resistant Glioma Cells via MMPs
(A) The short-term cultured cell lines NCH89, -125, and -270 were incubated with the indicated concentrations of CD95L-T4 or Staurosporin (St., 1 mM) or left
untreated (Co). After 24 hr DNA fragmentation was analyzed by FACS (upper panels). (Lower panels) FACS analysis of CD95 surface expression in the
NCH89, -125, and -270.
(B) NCH cells were treated for 48 hr with aApo-1 or left untreated, to detect single-cell migration through a Boyden chamber with 8 mm pore size.
(C and D) NCH89, -125, and -270 cells were treated with aApo-1 for 48 hr. Expression of MMP-2 (C) and MMP-9 (D) was measured by quantitative real-time PCR.
(E) NCH125 cells were transfected with a siRNA pool against MMP-2 and MMP-9 (shMMPs) or with Lipofectamine alone (Lipo). Forty-eight hours after transfec-
tion, cells were treated with CD95L-T4, and migration was measured in a two-dimensional migration assay 48 hr later.
(F) Expression of MMP-2 and MMP-9 as measured by quantitative-RT-PCR. Results are expressed as mean ± SE (*p < 0.05; **p < 0.001; ***p < 0.0001) and are
representative of at least two independent experiments.polyposis coli (APC), and axin proteins—the degradation com-
plex. Phosphorylation of b-catenin by GSK3b targets it for pro-
teasomal degradation. As a consequence of GSK3b inhibition,
b-catenin accumulates and translocates into the nucleus, where
it engages the N terminus of DNA-binding proteins of the TCF
(T cell factor)/Lef (lymphoid-enhancing factor) family (Eastman
and Grosschedl, 1999), inducing expression of different target
genes, including c-Jun, an essential transcription factor for238 Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc.MMP-9 expression (Gum et al., 1996; Sato and Seiki, 1993).
Alternatively, inhibition of GSK3b activity can directly increase
AP-1 expression (Troussard et al., 2000). To study whether stim-
ulation of CD95 triggers b-catenin’s transcriptional activity, we
examined expression of cytoplasmic and nuclear b-catenin
and b-catenin’s transcriptional reporter activity. LiCl, a known
inhibitor of GSK3b and inducer of b-catenin’s transcriptional
activity, was used as a positive control. In T98G cells, triggering
Cancer Cell
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Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc. 239of CD95 induced cytoplasmic accumulation of b-catenin 30 min
after stimulation with CD95L-T4 (Figure 3E). Further, nuclear
translocation of active b-catenin, nonphosphorylated on the
GSK-targeted Ser 37 or Thr 41, was observed (Figure 3F).
TCF/Lef-reporter activity (TOP-FLASH) was also significantly
induced upon CD95L-T4 (Figure 3G). Mutation of the TCF/Lef-
binding domain abolished CD95L-T4 induction of luciferase
activity (FOP-FLASH; Figure 3G). Additionally, activity of NFkB
increased significantly 8 hr after stimulation with 20 but not
10 ng/ml CD95L-T4 (Figure 3H). Taken together, activation of
CD95 induces migration/invasion through the PI3K/AKT/
GSK3b/b-catenin/MMP and possibly the PI3K/AKT/NFkB/
MMP pathway. Involvement of the latter pathway will be the
subject of future studies.
PI3K Is Activated via Recruitment of Src to CD95
As CD95 is not a receptor tyrosine kinase, a promising candidate
connecting CD95 to PI3K could be a nonreceptor tyrosine kinase
of the Src family kinases. To investigate whether Src connects
CD95 to PI3K activity, we performed coimmunoprecipitation
experiments (Figures 4A–4C). Indeed, treatment of T98G and
LN18 cells with CD95L-T4 induced recruitment of Src and the
p85 subunit of PI3K to CD95. Association of p85 with CD95
was examined by immunoprecipitating either CD95 or p85.
The degree of association of p85 with CD95 inversely correlated
with the concentration of CD95L-T4 in T98G cells (Figure 4B).
However, in LN18 cells p85 recruitment to CD95 was only de-
tected at high concentrations of CD95L-T4 (Figure 4A). Immuno-
precipitation of CD95 allowed detection of a Src family member
at 5 min after treatment with low concentration of CD95L-T4 (Fig-
ures 4A and 4B). Src association decreased at a higher concen-
tration (Figures 4A and 4B). Thus, at low concentrations of
CD95L-T4 both Src and p85 associated at detectable levels
with CD95 in T98G cells, but in LN18 cells only Src was detected.
Further, after a screening with antibodies to several SFKs, such
as Fyn, Lyn, pp60, and Yes, we identified Yes as the Src family
member that links CD95 to PI3K (Figure 4C). To validate the
role of Yes in the migration of glioma cells, knockdown experi-
ments were performed. In cells transfected with Yes siRNA,
expression of Yes, as assessed by FACS and qRT-PCR, was
reduced, while Fyn expression, another Src family member,
remained unaffected (Figure 4E). siRNA to Yes, but not to Fyn,
significantly abolished CD95L-T4-induced migration of T98G
and of NCH125 cells (Figure 4D). This block of migration was res-
cued by Yes overexpression in T98G and LN18 cells (Figure 4F).
Like the PI3K inhibitor LY290059, siRNA to Yes also inhibited
CD95-induced phosphorylation of AKT (Figure 4G).
Inefficient DISC Formation in Apoptosis-Resistant
Glioma Cells
If Yes and p85 get recruited to CD95 in both apoptosis-prone
and -resistant cells, what determines the fate of the cell? To
address this issue, we examined the role of the PI3K pathway
repressor PTEN (MMAC1, TEP1). While the apoptosis-prone
LN18 cells have an intact PTEN, T98G cells carry a point muta-
tion (codon 42 CTT to CGT; Glycine to Glutamine) in one allele
and lack of the second allele of PTEN and a total loss of one of
the chromosomes 10 (Fan et al., 2002; Furnari et al., 1997).PTEN overexpression, however, did not sensitize T98G or
NCH125 cells to CD95-mediated apoptosis (Figure 5A).
We further questioned whether caspases were involved in
CD95-induced activation of PI3K. Inhibition of caspases by the
general caspase inhibitor zVAD-fmk did not prevent GSK3b
phosphorylation (Figure 5B). Likewise, CD95-induced cleavage
of Caspase-8 could only be detected in LN18 but not in T98G
cells (Figure 5C). To investigate if DISC components were effi-
ciently recruited in these cells, we analyzed FADD recruitment
in CD95-immunoprecipitates. Whereas upon stimulation with
CD95L-T4 recruitment of FADD to CD95 increased in LN18 cells,
no increase was detected in T98G cells (Figure 5D). Accordingly,
Caspase-8 recruitment to CD95 increased upon stimulation with
CD95L-T4 in LN18 and J16 cells but not in T98G cells (Figure 5D).
Most importantly, in T98G cells, siRNA knockdown of Yes
enabled CD95L-T4 induction of FADD recruitment to CD95
(Figure 5E). Along this line, while expression levels of FADD
were similar in LN18 and T98G cells, Yes levels were significantly
higher in T98G cells (Figure 5F). As opposed to Yes, Fyn expres-
sion was significantly higher in LN18 cells (Figure 5F). Taken
together, we propose that CD95 mediates invasion via the
Yes/PI3K/AKT/GSK3b/MMP pathway (Figure 6).
The CD95/CD95L System Is an Important Mediator
of Glioma Invasion In Vivo
Expression of CD95L in patients suffering from GBM showed
a triangle-like distribution of CD95L in every tumor examined
(Figure 7A). Inside the tumor, only small amounts of CD95L
were expressed (Figure 7Aa). Expression increased at the
tumor/host interface, peaked in the brain parenchyma adjacent
to the tumor (Figure 7Ab), and decreased again with increasing
distance to the glioma (Figure 7Ac). CD95L was detected in
tumor cells, neurons, and macrophages (data not shown). Addi-
tional expression of CD95L within the tumor was observed in
glioma cells surrounding tumor vessels. Likewise, phosphoryla-
tion of Src family kinases (pSrc) and Yes expression were consis-
tently found at the tumor/host interface in every examined sam-
ple, suggesting a role in tumor invasion (Figure 7B). Within solid
tumor areas, expression of Yes highly varied between tumor
samples, from very high to expression only in scattered tumor
cells. In these highly Yes-expressing areas phosphorylation of
Src was either not detected or rather limited (Figure 7B).
For translation of our findings into a more physiological in vivo
setting, we examined the role of the CD95/CD95L system in
a mouse model of GBM. For these studies, the established
murine glioma cell line SMA-560 was injected intracranially into
a syngeneic Vm/Dk host (Ashley et al., 1998). The use of a synge-
neic tumor model was important to allow the tumor’s induction of
CD95L expression in the surrounding brain tissue.
SMA-560 cells expressed only low levels of CD95 receptor on
their surface (Figure 8A) and no CD95L at all (Figure 8B), when
kept under cell culture conditions. As reported by others (Ashley
et al., 1998), we found SMA-560 cells to be resistant to CD95-
induced apoptosis (data not shown). Following formation of spher-
oids, the levels of CD95 slightly increased (Figure 8A), whereas
FACS analysis failed to identify CD95L at the cell surface (Fig-
ure 8B). Despite the relatively low CD95 surface levels, spheroids
of thesecellsdisplayed increasedmigration in thecollagen invasion
assayafterCD95stimulation inaconcentration-dependentmanner
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CD95 Triggers Invasion of Glioblastoma CellsFigure 3. CD95 Induces Migration via the PI3K/AKT/GSK3b Pathway
(A) Phosphorylation of AKT and ERK is shown in T98G and LN18 cells upon treatment with CD95L-T4 at the indicated time points.
(B) In T98G, LN18, and NCH125 and -270 cells, but not in NCH89, phosphorylation of AKT exhibited a concentration-dependent bell shape after stimulation with
CD95L-T4.
(C) In T98G cells, treatment with CD95L-T4 (10 ng/ml) and aApo-1 (1 mg/ml) induced GSK3b phosphorylation. Kinetics of GSK3b inhibition exhibited a bell-
shaped curve.
(D) T98G cells were infected with an empty lentiviral vector (Co) or a constitutively active GSK3b mutant (GSK S9A). At 36 hr GSK S9A-infected T98G cells
migrated significantly less than their empty vector counterparts upon treatment with aApo-1 or CD95L. A neutralizing antibody to CD95L (Nok1) blocked
CD95L-induced migration of vector- and GSK S9A-infected cells. Results are expressed as mean ± SE (*p < 0.05; **p < 0.001) and are representative of two
independent experiments.
(E) b-Catenin accumulated in the cytosol of T98G cells 30 min after treatment with CD95L-T4 (10 ng/ml).
(F) Active b-catenin (green) translocated into the nucleus upon stimulation with aApo-1. DAPI (blue) and P-GSK3b (red) were used to visualize the nuclei and the
cytosol, respectively, in T98G cells.240 Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc.
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CD95 Triggers Invasion of Glioblastoma CellsFigure 4. Src and p85 Associate to CD95 to Activate AKT
(A and B) LN18 and T98G cells were stimulated with CD95L-T4 for the indicated time points and concentrations. (Left panels) CD95 was immunoprecipitated, and
the immunoprecipitates were immunoblotted with anti-p85, anti-CD95, and anti-Src antibodies. (Middle panels) p85 was immunoprecipitated, and the immuno-
precipitates were probed with anti-p85 and anti-CD95 antibodies. Protein-A beads are included as a negative control. Whole cellular lysates (WCL) probed with
anti-p85, anti-CD95, and anti-Src are shown on the right panels.
(C) T98G cells were treated for the indicated times and concentrations with CD95L-T4. CD95 was immunoprecipitated, and immunoprecipitates were immuno-
blotted with anti-Yes antibody.
(D) T98G and NCH125 cells were transfected with siRNA against Yes or Fyn or with Lipofectamine alone (Lipo). Seventy-two hours after transfection, cells were
treated with CD95L-T4, and 24 hr afterwards migration was measured in a two-dimensional migration assay.
(E) Expression of Yes-mRNA as measured by quantitative-RT-PCR and Yes protein levels as assessed by FACS analysis are shown.
(F) T98G and NCH125 cells were transfected with siRNA against Yes, a Yes overexpression plasmid (pCMV-Yes), or both. Seventy-two hours after transfection,
cells were treated with CD95L-T4, and 24 hr afterwards migration was measured in a two-dimensional migration assay.
(G) Yes siRNA and the PI3K inhibitor (LY 290059) blocked CD95-induced phosphorylation of AKT. P, phosphorylated; T, total; *specific band; n.s., unspecific band.
(D and F) Results are expressed as mean ± SE (*p < 0.05; **p < 0.001; ***p < 0.0001) and are representative of two independent experiments.(Figure 8C). In accordance with our finding that spheroids do not
express CD95L (Figure 8B), blockage of CD95L using the CD95L-
neutralizing antibody MFL3 did not alter invasion (Figure 8C).
Interestingly, when cells isolated from solid tumors were ana-
lyzed 14 and 18 days after inoculation, surface levels of CD95
and CD95L significantly increased (Figures 8A and 8B). This
indicates the requirement of tumor/host interaction and, there-
fore, of a crosstalk between host factors and tumor cells as given
in the case of murine GBM-model.(G and H) Twenty-four hours after transient transfection of T98G with the b-Ca
FLASH; [G]), or the NFkB-reporter construct (NFkB-Luc; [H]); cells were treated
tivity was assayed 12 hr (G) or 8 hr (H) afterwards and normalized to renilla lucFor a more detailed analysis of the functional significance
of this increase, we extracted fragments from solid tumors
14 days after intracranial injection of cells. These cells were
preincubated with either medium alone, medium with CD95L-
neutralizing antibody (MFL3), or the appropriate isotype anti-
body, respectively. After embedding into collagen gels, migra-
tion was monitored for a period of 72 hr (Figure 8D). Strikingly,
preincubation with the CD95L-neutralizing antibody MFL3,
but not with the isotype or medium alone, reduced migrationtenin/TCF transcriptional reporter (TOP-FLASH; [G]), the control plasmid (FOP-
with CD95L-T4 (G and H) or LiCl (G), or left untreated (G and H). Luciferase ac-
iferase expression. P, phosphorylated; T, total. Scale bar, 20 mm.
Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc. 241
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CD95 Triggers Invasion of Glioblastoma CellsFigure 5. Inefficient DISC Formation in
Apoptosis-Resistant Glioma Cells
(A) Forty-eight hours after transient transfection of
T98G and NCH125 with either a HA-PTEN (PTEN)
or the empty vector (Mock), cells were treated with
CD95L-T4 (500 ng/ml). To detect cell death in
PTEN-overexpressing cells, an intracellular FACS
staining against the HA-tag was performed. There-
after, forward side scatter analysis was performed
in HA-positive cells. Results are expressed as
mean ± SE and are representative of two indepen-
dent experiments.
(B) T98G cells were treated for 1 hr with aApo-1,
zVAD-fmk, or a combination of zVAD-fmk and
aApo-1, or left untreated (Co). Phosphorylation of
GSK3b was analyzed by western blot.
(C) Cleavage of Caspase-8 in T98G, LN18, and
Jurkat 16 (J16) was detected by western blot anal-
ysis at 5 min after CD95 stimulation.
(D) In T98G and LN18 cells treated with CD95L-T4
for 5 min, either CD95 (upper panels) or Caspase-8
(lower panels) was immunoprecipitated. The im-
munoprecipitates were immunoblotted with anti-
FADD antibody and anti-CD95 (upper panels)
and with anti-CD95 and anti-Caspase-8 (lower
panels). Jurkat cells were included as a positive
control.
(E) T98G cells were transfected with either Yes
shRNA or a nontargeting shRNA as a negative
control. After 72 hr, cells were treated with
CD95L-T4 or left untreated, and immunoprecipita-
tion of CD95 was performed; the immunoprecipi-
tates were then immunoblotted with anti-FADD
antibody, and the IgG heavy chain serves as load-
ing control. On the right, knockdown efficiency
assessed by quantitative-RT-PCR is shown.
(F) Quantitative expression of FADD, Yes, and Fyn
in T98G and LN18 cells was measured by FACS
analysis. Results are expressed as mean ± SD
(*p < 0.05) and are representative of three indepen-
dent experiments. MFI, mean fluorescence inten-
sity; P, phosphorylated; T, total.
sphere (Figure 8E). We conclude from
these data that the CD95/CD95L system
is a major mediator of malignant glioma
invasion into the surrounding brain
in vivo.
DISCUSSION
The CD95/CD95L system is generally
appreciated for its role in inducing apo-
ptosis (Krammer, 2000). However,
evidence accumulates that CD95 can
mediate apoptosis-independent pro-
cesses such as proliferation, angiogene-of cells out of the tumor core by approximately 50% (Fig-
ure 8D).
To verify these results in vivo, we injected GFP-positive SMA-
560 cells and MFL3 or the appropriate isotype antibody into the
left striatum of Vm/Dk mice. Treatment with MFL3 significantly
reduced migration of tumor cells into the contralateral hemi-
sis, fibrosis, and inflammation (Biancone et al., 1997; Hohlbaum
et al., 2002). Overexpression of CD95 in Lewis lung carcinoma
cells resulted in a survival advantage of tumor cells in vivo (Lee
et al., 2003). Along the same line, triggering of CD95 has been re-
ported to drive cell-cycle progression in glioma cells (Shinohara
et al., 2000). In malignant astrocytoma, CD95 ligation promoted242 Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc.
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CD95 Triggers Invasion of Glioblastoma Cellsexpression of proinflammatory chemokines and angiogenesis
(Choi et al., 2001, 2002, 2003). Here, we report that triggering
of CD95 in glioblastomas initiates a cascade of signaling events
ultimately leading to increased migration. CD95-induced migra-
tion was first observed in cultured renal tubular cells (Jarad et al.,
2002) and has recently been reported for ovary, breast, lung, and
kidney tumor cells (Barnhart et al., 2004). In the latter study, a se-
rum gradient was added to the CD95 stimulus in order to insti-
gate and direct cell migration (Barnhart et al., 2004). Glioblas-
toma cells, on the contrary, are characterized by their invasion-
prone phenotype and do migrate in the absence of an additional
stimulus. This highly invasive behavior could be blocked in vitro,
ex vivo, and in vivo by the sole neutralization of CD95 activity, in-
dicating that CD95/CD95L contributes to the invasion-prone
phenotype of malignant glioma cells.
To invade and spread into the surrounding normal brain, tumor
cells need to digest components of the extracellular matrix
(ECM), including fibronectin, laminin, and type IV collagen. The
best characterized family of ECM-degrading enzymes is the
MMP family. MMP-9-deficient glioblastomas are less invasive
in vitro and in vivo (Rao, 2003). Glioblastomas produce signifi-
cantly higher levels of MMP-9 than do lower-grade gliomas
and normal brain tissue (Rao, 2003). Levels of MMP-9 increased
during the growth of glioblastoma cells that had been implanted
intracranially in nude mice (Sawaya et al., 1998). Furthermore,
these proteases play a role in establishing and maintaining a
microenvironment that facilitates tumor cell survival. Accord-
ingly, MMPs regulate tumor angiogenesis, and inhibition of
MMP-9 reduced capillary-like structures in mixed cultures of en-
dothelial and glioma cells (Rao, 2003). The same features hold
true for CD95L expression: (1) levels positively correlate with
the degree of malignancy (Choi et al., 2001; Frei et al., 1998;
Figure 6. Schematic Model for CD95 Signaling of Invasion in Glio-
blastoma
CD95L induces recruitment of the Src family member Yes and the p85 subunit
of PI3K (depicted here by its two subunits: p85 and p110) to CD95, thereby
activating AKT. Activated AKT phosphorylates and inactivates GSK3b, allow-
ing b-catenin translocation into the nucleus, where it induces transcription of
MMPs. This signaling pathway could be blocked by siRNA against Yes, or
MMP-2 and -9, the PI3K-specific inhibitor (Ly290059), or by lentiviral infection
with a dominant-active mutant of GSK3b (S9A).Weller et al., 1994); (2) levels increase after intracranial inocula-
tion; (3) in human specimens of GBM, one of its preferential local-
izations is at the tumor vessels. Here we show that triggering of
CD95 greatly increases mRNA expression of MMP-9 and MMP-
2 in established glioblastoma cell lines and primary cultures, and
knockdown of MMP-2 and MMP-9 blocks CD95-induced migra-
tion. The promoter region of MMP-9 contains putative binding
sites for AP-1, NFkB, Sp1, and AP-2 (Sato and Seiki, 1993).
The AP-1 transcription complex plays an essential role in stimu-
lating transcription of MMP-9 (Gum et al., 1996; Sato and Seiki,
1993). c-Jun, a putative component of the AP-1 transcription
complex, has been identified as one of the most highly induced
TCF/b-catenin target genes (Mann et al., 1999; Staal et al., 2004).
Inhibition of GSK3b, as reported here, allows unphosphorylated
b-catenin to accumulate and translocate into the nucleus, where
it functions as a cofactor for transcription factors of the TCF/Lef
family (Reya and Clevers, 2005). In addition, activity of NFkB was
concomitantly observed. Since CD95L-T4 decreases ERK activ-
ity, we believe that in T98G cells AKT regulates NFkB activity
through phosphorylation/activation of the IKK kinase, which in
turn phosphorylates IkB and allows the release of activated
NFkB (Ozes et al., 1999). Alternatively, IkB can transactivate
the p65 subunit (Madrid et al., 2000). In contrast, the induction
of motility and invasiveness previously reported for tumor cell
lines of endodermal or mesodermal origin involves ERK and Cas-
pase-8 activity (Barnhart et al., 2004). Thus, activation of CD95
induces migration/invasion through the PI3K/AKT/GSK3b/b-cat-
enin/MMP and perhaps the PI3K/AKT/NFkB/MMP pathway.
In the past, several reports have pointed out an important role
for tyrosine phosphorylation in CD95-induced signaling (Eischen
et al., 1994; Schlottmann et al., 1996). These preliminary reports,
however, suggested that CD95-induced tyrosine phosphoryla-
tion is a prerequisite for CD95-mediated apoptosis (Eischen
et al., 1994; Gulbins et al., 1998; Schlottmann et al., 1996). Along
this line, the phosphatases SHP-1, SHP-2, and SHIP were found
to associate with CD95 to counteract survival factor-initiated
pathways (Daigle et al., 2002). Just recently, Src-induced tyro-
sine phosphorylation of Caspase-8 was found to impair CD95-
induced apoptosis (Cursi et al., 2006). We now describe associ-
ation of the Src family member Yes and p85 with CD95.
TRANCE, another TNF family member, activates PI3K through
a signaling complex involving c-Src and TRAF6 (Wong et al.,
1999). Inhibition of Fyn, another Src family member, decreased
CD95-induced migration of glioblastoma cells, although not sig-
nificantly. This can be explained by the fact that Fyn is involved
in EGFR-mediated signaling in neural cells (Stirnweiss et al.,
2006) and EGFR is a very important receptor for glioma invasion
that has been found in association with CD95 (Eberle et al.,
2005). Thus, inhibition of CD95-mediated signaling might affect
EGFR-mediated signaling and vice versa. Whether another
adaptor molecule is still missing in CD95’s PI3K-activation com-
plex (PAC) remains a subject for future studies. Alternatively, Yes
and p85 might directly interact with CD95. Accordingly, in T98G
cells, knockdown of Yes enabled CD95L-T4-induced recruit-
ment of FADD to CD95, indicating that Yes and FADD might
compete for binding to CD95. Along this line, analysis of Yes
expression levels revealed a much higher expression in T98G
than in LN18 cells. Most importantly, expression of Yes and
phosphorylation of Src family kinases was consistently foundCancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc. 243
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indicating its involvement in tumor invasion.
Barnhart et al. (2004) previously showed that exogenous
CD95L induces migration of tumor cells from endodermal origin
in vitro. In these cells CD95L induces migration via Caspase-8
and ERK (Barnhart et al., 2004). These authors speculate that
CD95L might be involved in the tumor’s escape from chemo-
and radiotherapy, since both treatments increase expression
of CD95L. In our study we found that CD95L also induces migra-
Figure 7. Expression of CD95L, Yes, and Phospho-Src in Clinical
Samples of GBM
(A) Representative immunohistochemical staining of CD95L (red) in primary
human GBM. Note the increased expression of CD95L at the tumor/host inter-
face (Ab) compared to more solid tumor areas (asterisk in [Aa]) or brain paren-
chyma (Ac).
(B) Immunohistochemical staining of phosphorylated Src family kinases
(p-Src; [Ba, Bc, Be, and Bf]) and Yes (Bb, Bd, Bg, and Bh). (Ba–Bd) Overview
of tumor infiltration zone; note robust phosphorylation of Src and expression of
Yes in zone of tumor/host interaction (to the left) and reduced or no p-Src in
solid tumor areas (to the right, as indicated by the asterisk). Yes expression
was found at the tumor/host interface (Bb, Bd, and Bg) and in scattered solid
tumor areas (Bh). Strong phosphorylation of Src in tumor cells in solid tumor
areas (Bf) and infiltration zone (Be). Scale bar, 50 mm.244 Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc.tion of GBM cells. Beyond this, the present study represents
a significant conceptual advance in the field of tumor biology be-
cause it shows that: (1) the sole interaction of tumor cells with the
surrounding parenchyma induces expression of CD95L in tumor
and host cells; (2) in GBM cells CD95L signals invasion via Yes/
PI3K/MMPs and not via Caspase-8/ERK, as it is the case in tu-
mor cells of endodermal origin; (3) neutralization of CD95
activity blocks the basal migration of GBM cells in vivo in a mouse
syngeneic model of GBM that mimics the clinical situation. In
addition, this study shows that the molecular stoichiometry of
the PI3K signaling components seems to determine the cellular
response to CD95.
In summary, our data indicate that, generally, WHO IV tumors
are resistant to CD95-induced apoptosis and instead increase
their invasion capacity upon stimulation of CD95. Current exper-
imental strategies targeting glioblastoma invasion focus on inhi-
bition of MMP activity by expression of the natural inhibitors
TIMP2 and TIMP4 or are based on direct gene targeting of
MMP mRNA by antisense strategies. Nevertheless, while
TIMP2 decreases angiogenesis and invasion, it also protects tu-
mor cells from apoptosis (Valente et al., 1998). Other strategies
to inhibit MMP production employ targeting the signal transduc-
tion pathways leading to their expression, which, however, are
involved not only in the induction of tumor invasion, but also in
some basic physiologic functions, thus making these strategies
less attractive for clinical application. While CD95 activity is
required for neurite remodeling during embryonic brain develop-
ment (Zuliani et al., 2006) and for the clearance of damaged cells
in the diseased brain (Demjen et al., 2004; Martin-Villalba et al.,
1999, 2001; Mattson, 2000), no CD95 protein is detectable in
the healthy adult brain. Thus, targeting CD95 should have fewer
side effects than other migration-inducing factors that are nor-
mally involved in normal brain function.
Here, we provide evidence that CD95 directly activates PI3K
to contribute to the invasion-prone phenotype of GBM. Consid-
ering that current treatments of GBM are not successful because
of the highly invasive nature of these brain tumors, finding
another therapeutic approach is of prime importance.
Here, we provide evidence that targeting the CD95/CD95L
system holds promise for the frontline therapy of human GBM.
EXPERIMENTAL PROCEDURES
Primary Samples
Tissue specimens of NCH tumors were obtained intraoperatively. Informed
consent was obtained from each patient according to the research proposals
approved by the Institutional Review Board at the Medical Faculty Heidelberg.
Fresh tissue was divided into two parts, one part to establish primary tumor
cultures and the other for RNA extraction.
Knockdown Experiments
Knockdown experiments were performed by transient transfection of siRNA
pools (Dharmacon) with Lipofectamine 2000 (Invitrogen Life Technologies) fol-
lowing the instruction manual. Migration experiments were performed using
either validated siRNA against Yes (QIAGEN SI00302218), and a second
siRNA, targeting a different member of the Src family kinases, Fyn (QIAGEN
SI00605451), which was used as a negative control, or pools of validated
shRNAmir-pGIPZ-vectors for Yes, MMP-2, and MMP-9 and a nontargeting
shRNAmir-pGIZ vector as a negative control (RHS 4430-98843955,
-98820654, -99161516, -98514235, -98709361, -99137419, -99291751,
-99298712, and -99138418, and RHS 4346-OB, respectively; Open
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CD95 Triggers Invasion of Glioblastoma CellsFigure 8. CD95 and CD95L Are Upregulated on Murine Glioma Cells In Vivo and Induce Migration
(A and B) CD95 and CD95L surface expression on the murine glioma cell line SMA-560 was determined under normal cell culture conditions, after the formation of
spheroids or following intracranial implantation. Changes were normalized to cell culture condition levels. Results represent three independent experiments and
are expressed as mean ± SD (*p < 0.05).
(C) Spheroid cultures were embedded into a collagen matrix and treated with antibodies to CD95 (Jo2), a neutralizing antibody to CD95L (MFL3), or the appro-
priate isotype control antibody at the indicated concentrations. The migration of cells was monitored over 48 hr, and the distance of cells to the spheroid’s border
is depicted (n = 10 cells, three spheroids per treatment).
(D) Experimental scheme. Migration of tumor explants into collagen after treatment with either MFL3 or the appropriate isotype control is depicted as described
above (n = 10, three spheroids per treatment).
(E) Representative pictures of GFP-immunostained isotype- or MFL3-treated SMA tumors. The tumor-bearing (ipsilateral) and contralateral hemispheres are
shown. Numbers of SMA-560 cells (GFP-positive) in the contralateral hemisphere of Vm/Dk mice treated with either MFL3 or the isotype control antibody
were counted and normalized to tumor area. Shown results are representative of two independent experiments and expressed as mean ± SD (*p < 0.05;
**p < 0.001). Scale bar, 100 mm.Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc. 245
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were cultured for 72 hr before treatment with CD95LT4 (10 ng/ml and 20 ng/
ml), and migration was analyzed 24 hr after treatment with a two-dimensional
migration assay. The knockdown was controlled by quantitative real-time PCR
and FACS. To exclude off-target effects of Yes-siRNA, cells were transfected
with siRNA against Yes, a Yes overexpression plasmid (p-CMV-Yes), or both
and cultured for 48 hr before being transferred to a migration plate. After an ad-
ditional 48 hr, cells were treated with CD95L-T4 (10 ng/ml and 20 ng/ml). Mi-
gration was measured 24 hr after treatment in a two-dimensional migration as-
say.
For immunoprecipitation studies, transfected cells were cultured for 72 hr
prior to treatment.
Animal Experiments
All animal experiments conform to the relevant regulatory standards and have
been approved by the ethical authorities (Regierungspra¨sidium Karlsruhe,
Germany). For intracranial injections, 8- to 12-week-old inbred Vm/Dk mice
were used. 5.000 SMA-560 cells were harvested by trypsinization, resus-
pended in 1 ml DMEM supplemented with 10% FCS, 1% penicillin/streptomy-
cin (PS), and 1% L-Glutamine (200 mM) and loaded into a 10 ml Flexilfil syringe
(WPI, Berlin, Germany). A burr hole was drilled 2.75 mm lateral to the bregma,
and the needle was introduced to a depth of 3 mm. Mice were sacrificed 7, 14,
or 18 days after injections.
Tumor Explants
Fourteen days after tumor inoculation, the mice were sacrificed, and the
tumors were extracted. Tumor explants were then incubated for 1 hr in either
medium, medium plus isotype control antibody (IgG 10 mg/ml), or medium with
MFL3 (10 mg/ml). Following embedding of the explants into collagen, cell inva-
sion was recorded over 72 hr with a time-lapse microscope (Olympus, Ger-
many).
Tumor Analysis
For analysis of CD95-induced migration in vivo, a suspension of 5.000 SMA-
560-GFP cells and 3 mg of MFL3 or the appropriate isotype antibody was
injected into the left striatum of Vm/Dk mice. After 1 week, mice were sacrificed
and the brains were extracted. Following immunohistochemical staining, GFP-
positive cells in the contralateral hemisphere of three representative areas per
sample were counted and normalized to the area of the tumor as assessed by
Cell^R software (Olympus, Germany).
Migration Assay
Migration of the glioma cells in vitro was measured by the migration through
Collagen I-coated (Chemicon) transwell inserts (Falcon). Cells (5 3 104) were
plated in 200 ml medium onto collagen-coated (50 mg/ml) transwell inserts
with 8 mm pore size. Twenty-four hours after plating, the cells were starved
with basal DMEM for an additional 24 hr before they were treated with
aApo-1 (1 mg/ml or 0.1 mg/ml + Protein-A for crosslinking), CD95L (10 ng/ml),
and CD95L-T4 (20 ng/ml). The number of completely migrated cells was
counted at 12, 24, and 48 hr after treatment. In every experiment triplicates
were counted for each treatment.
Genetic Engineering of Human CD95-Ligand-T4
The TRAIL/DR5 complex and the TNF-a structure were used as models to de-
velop expression strategies for the human CD95L-receptor binding domain
(CD95L-RBD). Provided that the structure of trimeric human CD95L-RBD is
in principle similar to the TNF-a or TRAIL-RBD structures (PDB entries: 1TNF
and 1D0G/1DU3, respectively [Cha et al., 1999; Eck and Sprang, 1989; Hymo-
witz et al., 1999]), the following observations were taken into account:
(1) The N- and C-terminal amino acids of the RBD from TRAIL and TNF-a
form an antiparallel b strand.
(2) The terminal amino acids of this b strand are located next to each other
at the same site of the molecule close to the central axis of the TRAIL-
RBD trimer (see Figure S1).
This means that, for steric reasons, the use of N and C termini in the same
molecule for the fusion of protein domains (e.g., for the addition of stabilization246 Cancer Cell 13, 235–248, March 2008 ª2008 Elsevier Inc.motifs or tags) is mutually exclusive. The ideal stabilization motif should be
a small, well-defined trimer located close to the central axis of the CD95L-
trimer with its N and C terminus at opposite sites of the stabilization motif in
order to minimize its risk of interference with the ligand/receptor interaction
sites. An appropriate trimeric protein domain fulfilling these criteria is the T4-
Foldon motif from the fibritin of the bacteriophage T4 (Guthe et al., 2004;
Meier et al., 2004).
According to the above-mentioned considerations, the T4-Foldon was
fused C-terminally to the human CD95L-RBD (Glu142-Leu281 of CD95L). Be-
tween the CD95L-RBD and the T4-Foldon, a flexible linker element
(GSSGSSGSSGS) was placed, and a hexahistidine tag and a streptag-II
(HHHHHHSAWSHPQFEK) were added C-terminally. This affinity tag was
linked to the T4-Foldon by a flexible linker element (SGPSSSSS). To allow
for secretory-based expression, a signal peptide from human Igk was fused
to the N terminus (Glu142). The proposed signal peptide cleavage site formed
by the fusion of the Igk leader to the CD95L-RBD is expected to release a final
product with a N-terminal located Glutamine, corresponding to Glu142 of
human CD95L. The amino acid sequence of the CD95L-T4-construct shown
in Figure S1C was back-translated and its codon usage optimized for mamma-
lian cell-based expression. Gene synthesis was done by ENTELECHON
GmbH (Regensburg, Germany). The final expression cassette was subcloned
into pCDNA4-HisMax-backbone, using unique HindIII and NotI sites of the
plasmid. A schematic summary, including all features described above, is
shown exemplarily for the TRAIL-T4-DR5-complex (Figure S1D).
Expression and Purification of CD95L-T4
HEK293T cells grown in DMEM + GlutaMAX (GibCo) supplemented with 10%
FBS, 100 units/ml penicillin, and 100 mg/ml Streptomycin were transiently
transfected with a plasmid encoding CD95L-T4. Cell culture supernatant con-
taining recombinant CD95L-T4 was harvested 3 days posttransfection and
clarified by centrifugation at 300 3 g followed by filtration through a 0.22 mm
sterile filter. For affinity purification, 1 ml Streptactin Sepharose (IBA GmbH,
Go¨ttingen, Germany) was packed to a column and equilibrated with 15 ml
buffer W (100 mM Tris-HCl, 150 mM NaCl [pH 8.0]). The cell culture superna-
tant was applied to the column with a flow rate of 4 ml/min. Subsequently, the
column was washed with buffer W, and bound CD95L-T4 was eluted stepwise
by addition of 73 1 ml buffer E (100 mM Tris-HCl, 150 mM NaCl, 2.5 mM Des-
thiobiotin [pH 8.0]). The protein content of the eluate fractions was analyzed by
SDS-PAGE and silver staining (Figure S1E). Fractions E2–E5 were subse-
quently concentrated by ultrafiltration and further analyzed by size exclusion
chromatography (SEC).
SEC was performed on a Superdex 200 column using an A¨kta chromatog-
raphy system (GE-Healthcare). The column was equilibrated with phos-
phate-buffered saline, and the concentrated, streptactin-purified CD95L-T4
(E2-E5) was loaded onto the SEC column at a flow rate of 0.5 ml/min. The elu-
tion of CD95L-T4 was monitored by absorbance at 280 nm. The apparent mo-
lecular weight of purified CD95L-T4 was determined based on calibration of
the Superdex 200 column with gel filtration standard proteins (Figures S1F
and S1G) (Bio-Rad GmbH, Mu¨nchen, Germany).
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
three supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/13/3/235/DC1/.
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